Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial.
Ursula A WhiteMark D FitchRobbie A BeylMarc K HellersteinEric RavussinPublished in: Diabetologia (2020)
Pioglitazone may elicit distinct differences in in vivo adipogenesis in subcutaneous adipose depots in women with obesity, with increased rates in the protective scFEM. Trial registration ClinicalTrials.gov NCT01748994 Funding This study was funded by R01DK090607, P30DK072476, and R03DK112006 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health. The Robert C. and Veronica Atkins Foundation. Graphical abstract.
Keyphrases
- insulin resistance
- quality improvement
- healthcare
- type diabetes
- high fat diet induced
- public health
- metabolic syndrome
- weight loss
- adipose tissue
- cardiovascular disease
- weight gain
- randomized controlled trial
- study protocol
- risk assessment
- climate change
- body mass index
- skeletal muscle
- health promotion
- glycemic control
- open label